Inhibition of pathological calcification

"Inhibition of pathological calcification" refers to any process or intervention that prevents or reduces abnormal calcium phosphate crystal deposition in non-skeletal tissues (such as blood vessels, heart valves, kidneys, or tumor microenvironments), which is a significant factor in diseases like atherosclerosis, chronic kidney disease, heart valve disease, and certain cancers. This process is a complex, multi-factorial phenomenon involving the interplay of extracellular vesicles, cell death, mineral-binding proteins, enzymatic activity (such as alkaline phosphatase and tissue-nonspecific alkaline phosphatase), inhibitors like pyrophosphate and matrix Gla protein, gasotransmitters (such as hydrogen sulfide), and inflammatory signaling[1][3][4][6]. However, "inhibition of pathological calcification" is a therapeutic goal or strategy, not a singular druggable molecular entity or canonical target[6][2][4].